Hansoh Pharma Signs ADC Strategic Partnership with Roche, Securing $510 Million Upfront Payment
nashnova research
Hansoh Pharma (翰森制药, 03692.HK) signed a strategic ADC partnership with Roche, locking in $510 million in guaranteed payments and unlocking over $15 billion in potential milestones — one of the largest global ADC-platform licensing deals from a Chinese biotech to date.
What exactly was signed?
Hansoh is licensing two pre-clinical ADC programs to Roche, and the two companies will co-develop multiple new programs using Roche-proposed targets built on Hansoh's proprietary ADC technology platform — a system that precisely links antibodies with cytotoxic drugs to target cancer cells.
The split is clean: Hansoh leads early development through global Phase Ia trials; Roche takes over from there for worldwide markets.
This means → Hansoh is not selling a single drug. It is selling the output capacity of an entire ADC platform — Roche is buying a "platform + pipeline" package.
How does the money work?
Guaranteed cash comes in two tranches: a $400 million upfront payment at signing, plus $110 million on the first anniversary — $510 million banked with certainty.
Potential milestone payments exceed $15 billion, triggered step by step across development, regulatory, and commercial milestones, plus tiered royalties on future product sales.
In plain terms = the $510 million is "sign-and-cash" money; the $15 billion is "only-if-the-drugs-work-and-sell" money — the first is locked in, the second depends on clinical and commercial execution.
What did Hansoh keep for itself?
Hansoh retains all development, registration, and commercialization rights in mainland China, Hong Kong, Macau, and Taiwan — Greater China revenue stays in-house.
The deal also grants Hansoh an option to designate up to two programs for participation in development outside Greater China, with additional upside from U.S. commercialization of those two programs.
This means → Hansoh is not simply handing its technology to a multinational and walking away. It kept the core home market and built in optionality to expand overseas.
Why Roche — and what does this deal signal?
Roche was founded in Basel, Switzerland, in 1896 and now operates in over 150 countries. It is among the deepest-invested global pharma companies in oncology.
This reflects a shift in global ADC competition — from "who files first" to "whose technology platform can produce pipelines at scale." Roche chose Hansoh for platform repeatability, not just a single pipeline asset.
The key validation ahead: whether Hansoh's ADC pipeline can ride this partnership into global clinical stages faster — that will determine how much of the $15 billion milestone pool actually converts to cash.
市场有风险，内容仅供研究参考，不构成投资建议。